Loading…
Gilead Sciences, Inc. is projected to rise to $149.55 by 2027, a +15% move from its current price of $129.83. GILD is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $127.55 | $129.88 | $132.25 | +0.04% |
| Jul 14 | $126.65 | $129.93 | $133.30 | +0.08% |
| Jul 15 | $125.98 | $129.99 | $134.12 | +0.12% |
| Jul 16 | $125.42 | $130.04 | $134.83 | +0.16% |
| Jul 17 | $124.94 | $130.09 | $135.46 | +0.20% |
| Jul 18 | $124.50 | $130.14 | $136.03 | +0.24% |
| Jul 19 | $124.11 | $130.19 | $136.57 | +0.28% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $124.11 | $130.19 | $136.57 | +0.28% |
| Week 2 | $122.02 | $130.56 | $139.70 | +0.56% |
| Week 3 | $120.52 | $130.93 | $142.23 | +0.84% |
| Week 4 | $119.31 | $131.29 | $144.47 | +1.13% |
| Week 5 | $118.31 | $131.66 | $146.52 | +1.41% |
| Week 6 | $117.43 | $132.03 | $148.44 | +1.69% |
| Week 7 | $116.66 | $132.40 | $150.26 | +1.98% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and Yeztugo for the treatment of HIV-1 infection in patients.
It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. It also provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases.
The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies.
The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
Gilead Sciences, Inc. trades at $131.27 per share and has a market cap of $162.98B. It holds the rank of 92 among listed equities. The stock’s current price and market position place it within a broad, widely followed healthcare equity universe.
The longer-run price outlook implied by the available forecast data shows a rising trajectory from the current level toward higher averages and potential upside through 2050. The forecast set includes a neutral view for 2026 and bullish momentum in subsequent years.
A major floor 11.9% below — a decisive break under it would weaken the trend.
The nearest floor, 6.4% below — buyers have tended to step in here.
The nearest ceiling, 5.0% above — a clean break opens room to run.
A major ceiling 14.4% above — clearing it would confirm fresh momentum.
Key GILD support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GILD market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $133.29 | Sell | $132.19 | Sell |
| MA 10 | $130.43 | Sell | $130.87 | Sell |
| MA 20 | $127.77 | Buy | $129.54 | Buy |
| MA 50 | $129.85 | Sell | $130.43 | Sell |
| MA 100 | $135.77 | Sell | $131.66 | Sell |
| MA 200 | $130.44 | Sell | $128.56 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.70 | Neutral |
| Stoch RSI (14) | 43.48 | Neutral |
| CCI (20) | 44.01 | Neutral |
| Williams %R (14) | -52.16 | Info |
| MACD (12,26,9) | 1.03 | Buy |
| ROC (12) | 3.82 | Buy |
| Bollinger %B (20,2) | 0.63 | Neutral |
| Stochastic %K (14) | 47.84 | Neutral |
| TRIX (15) | -0.02 | Sell |
| Awesome (5,34) | 4.49 | Buy |
| Ultimate (7,14,28) | 57.26 | Neutral |
| Momentum (10) | 5.99 | Buy |
| Aroon Osc (25) | 68.00 | Buy |
| Hull MA (9) | 135.87 | Sell |
| ADX (14) | 15.04 | Neutral |
| ATR (14) | 2.15 | Info |
The 30-day technical picture is currently bullish. The RSI(14) is 60, and the moving-average backdrop shows the SMA50 at $129.60 and the SMA200 at $129.92. This combination suggests constructive near-term momentum.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $118.30 | $129.83 | $168.57 | 0% | Neutral | |
| $122.48 | $149.55 | $190.90 | +15% | Neutral | |
| $125.54 | $156.16 | $204.73 | +20% | Bullish | |
| $146.61 | $185.18 | $247.96 | +43% | Bullish | |
| $172.73 | $221.13 | $301.42 | +70% | Bullish | |
| $184.09 | $238.55 | $330.31 | +84% | Bullish | |
| $204.16 | $267.54 | $375.72 | +106% | Bullish | |
| $211.70 | $280.35 | $398.81 | +116% | Bullish | |
| $216.69 | $289.81 | $417.19 | +123% | Bullish | |
| $236.19 | $318.88 | $464.15 | +146% | Bullish | |
| $339.12 | $477.53 | $728.41 | +268% | Bullish | |
| $593.49 | $896.30 | $1,465.52 | +590% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $118.30 | $129.83 | $153.42 | +0.00% |
| August 2026 | $113.71 | $133.10 | $159.15 | +2.52% |
| September 2026 | $114.49 | $134.66 | $162.28 | +1.17% |
| October 2026 | $112.80 | $133.21 | $161.60 | -1.07% |
| November 2026 | $113.57 | $134.59 | $164.18 | +1.04% |
| December 2026 | $115.64 | $137.49 | $168.57 | +2.15% |
Click any year to see its month-by-month GILD forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, GILD is projected to trade between $118.30 and $168.57, averaging $129.83 — a potential gain of 0% from today's $129.83. A consolidation phase looks the most probable path here.
Gilead Sciences, Inc.'s 2027 outlook centres on $149.55, within a $122.48 to $190.90 range. That is up +15% on the projected 2026 average. That marks a +15% change versus current levels. Price action looks broadly range-bound.
By 2028, GILD could reach as high as $204.73, with a base case around $156.16 and support toward $125.54 — roughly +20% from $129.83. Buyers look set to stay in control over this stretch.
Expect GILD to range from $146.61 to $247.96 through 2029. The $185.18 average target implies a +43% move from current prices. That is up +19% on the projected 2028 average. Momentum favours further upside here.
The GILD price prediction for 2030 points to an average of $221.13 (low $172.73, high $301.42) — a potential gain of +70% on today's $129.83. Buyers look set to stay in control over this stretch.
In 2031, GILD is projected to trade between $184.09 and $330.31, averaging $238.55 — a potential gain of +84% from today's $129.83. That is up +8% on the projected 2030 average. Momentum favours further upside here.
Gilead Sciences, Inc.'s 2032 outlook centres on $267.54, within a $204.16 to $375.72 range. That is up +12% on the projected 2031 average. That marks a +106% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, GILD could reach as high as $398.81, with a base case around $280.35 and support toward $211.70 — roughly +116% from $129.83. Momentum favours further upside here.
Expect GILD to range from $216.69 to $417.19 through 2034. The $289.81 average target implies a +123% move from current prices. That is up +3% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The GILD price prediction for 2035 points to an average of $318.88 (low $236.19, high $464.15) — a potential gain of +146% on today's $129.83. Momentum favours further upside here.
In 2040, GILD is projected to trade between $339.12 and $728.41, averaging $477.53 — a potential gain of +268% from today's $129.83. That is up +50% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Gilead Sciences, Inc.'s 2050 outlook centres on $896.30, within a $593.49 to $1,465.52 range. That is up +88% on the projected 2040 average. That marks a +590% change versus current levels. Momentum favours further upside here.
Investing $1,000 in GILD today (≈ 7.70238 GILD) could be worth
$6,903.67
+$5,903.67 (+590%) by 2050 · US Dollar
Based on the average projected GILD price of $896.3 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GILDwould be worth at today's price.
$1,000 invested in GILD on Jul 10, 2025 (≈ 8.730574 GILD) would be worth
$1,133.49
+$133.49 (+13.3%) today · 1.13× · US Dollar
Based on a GILD entry price of $114.54 vs. today's $129.83.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $131.27 | $989.03 | -1.1% |
| 1 month ago | $121.48 | $1,068.74 | +6.9% |
| 3 months ago | $138.99 | $934.1 | -6.6% |
| 6 months ago | $122.6 | $1,058.97 | +5.9% |
| 1 year ago | $114.54 | $1,133.49 | +13.3% |
| All time (5.0y) ago | $68.01 | $1,908.98 | +90.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GILD forecast.
Our base-case forecast reaches $260.00 around 2032.
Implied market cap at $260.00: $322.81B
Looking further out, the multi-year forecast shows a rising average price path with a bullish bias starting in 2027. For 2030, the average forecast is $224.73 with a max of $306.45 and a min of $175.49, delivering an implied ROI of 71.2% and a bullish stance. The trajectory continues with 2040 at an average of $492.15 (max $750.86, min $349.44) and an ROI of 274.9%, then 2050 at an average of $919.03 (max $1,502.90, min not shown) with an ROI of 600.1% and a bullish sentiment.
Years such as 2027 ($150.59 avg) and 2028 ($160.32 avg) show continued gains, with 2035 ($325.32 avg) also reflecting strength. While these are estimates, they indicate an upward price path and substantial upside potential, tempered by the inherent uncertainty of markets.
Tap a question to reveal the answer.
2030 — avg $224.73; min $175.49; max $306.45; ROI 71.2; sentiment BULLISH.
The forecast shows a rising average price from 2026 to 2050 with bullish sentiment in the later years. 2026 avg $131.27, 2027 avg $150.59, 2040 avg $492.15, and 2050 avg $919.03, with ROI reaching 600.1 by 2050. These are estimates, not guarantees.
Yes. The 2030 max forecast is $306.45, which exceeds $300 (2029 max is $253.26). These figures are part of the given forecast paths.
Current price is $131.27 and market cap is $162.98B. The asset is ranked 92.
2040 — avg $492.15; max $750.86; min $349.44; ROI 274.9; sentiment BULLISH.
Gilead Sciences, Inc. Community Discussion
0Share your Gilead Sciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.